Novel Agonist and Antagonist Radioligands for the GLP-2 Receptor. Useful Tools for Studies of Basic GLP-2 Receptor Pharmacology
Overview
Authors
Affiliations
Background: Glucagon-like peptide-2 (GLP-2) is a pro-glucagon-derived hormone secreted from intestinal enteroendocrine L cells with actions on gut and bones. GLP-2(1-33) is cleaved by DPP-4, forming GLP-2(3-33), having low intrinsic activity and competitive antagonism properties at GLP-2 receptors. We created radioligands based on these two molecules.
Experimental Approach: The methionine in position 10 of GLP-2(1-33) and GLP-2(3-33) was substituted with tyrosine (M10Y) enabling oxidative iodination, creating [ I]-hGLP-2(1-33,M10Y) and [ I]-hGLP-2(3-33,M10Y). Both were characterized by competition binding, on-and-off-rate determination and receptor activation. Receptor expression was determined by target-tissue autoradiography and immunohistochemistry.
Key Results: Both M10Y-substituted peptides induced cAMP production via the GLP-2 receptor comparable to the wildtype peptides. GLP-2(3-33,M10Y) maintained the antagonistic properties of GLP-2(3-33). However, hGLP-2(1-33,M10Y) had lower arrestin recruitment than hGLP-2(1-33). High affinities for the hGLP-2 receptor were observed using [ I]-hGLP-2(1-33,M10Y) and [ I]-hGLP-2(3-33,M10Y) with K values of 59.3 and 40.6 nM. The latter (with antagonistic properties) had higher B and faster on and off rates compared to the former (full agonist). Both bound the hGLP-1 receptor with low affinity (K of 130 and 330 nM, respectively). Autoradiography in wildtype mice revealed strong labelling of subepithelial myofibroblasts, confirmed by immunohistochemistry using a GLP-2 receptor specific antibody that in turn was confirmed in GLP-2 receptor knock-out mice.
Conclusion And Implications: Two new radioligands with different binding kinetics, one a full agonist and the other a weak partial agonist with antagonistic properties were developed and subepithelial myofibroblasts identified as a major site for GLP-2 receptor expression.
Lipid regulation of the glucagon receptor family.
Oqua A, Manchanda Y, McGlone E, Jones B, Rouse S, Tomas A J Endocrinol. 2024; 261(3).
PMID: 38614123 PMC: 11103681. DOI: 10.1530/JOE-23-0335.
New Insights into the Structure and Function of Class B1 GPCRs.
Cary B, Zhang X, Cao J, Johnson R, Piper S, Gerrard E Endocr Rev. 2022; 44(3):492-517.
PMID: 36546772 PMC: 10166269. DOI: 10.1210/endrev/bnac033.
Gabe M, Gasbjerg L, Gadgaard S, Lindquist P, Holst J, Rosenkilde M Br J Pharmacol. 2022; 179(18):4473-4485.
PMID: 35523760 PMC: 9541843. DOI: 10.1111/bph.15866.
Gadgaard S, van der Velden W, Schiellerup S, Hunt J, Gabe M, Windelov J Br J Pharmacol. 2021; 179(9):1998-2015.
PMID: 34855984 PMC: 9303331. DOI: 10.1111/bph.15766.